Trial results for a study investigating Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion for various forms of leukemia and related conditions were posted on ClinicalTrials.gov on 2025-10-30. The study reported a 0.0 Percentage of participants for cumulative incidence of Grade III or Higher Acute Graft-versus-Host Disease (GVHD).
Background
Leukemia, Myelodysplastic Syndromes, and Hemophagocytic Lymphohistiocytoses are severe medical conditions often requiring allogeneic hematopoietic cell transplantation (allo-HCT). While allo-HCT can be curative, it carries a significant risk of complications, most notably graft-versus-host disease (GvHD), which can lead to high morbidity and mortality. Current strategies aim to mitigate GvHD while preserving the beneficial graft-versus-leukemia effect. This trial explored a specific approach using ex-vivo T cell receptor Alpha/Beta+ and CD19 depletion during haploidentical HCT, a method designed to substantially decrease the risk of GvHD and potentially eliminate the need for post-transplant immunosuppressive therapy.
Trial design
This study, designated as Phase NA, enrolled 3 participants. It investigated conditions including Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, and Hemophagocytic Lymphohistiocytoses. The intervention involved hematopoietic cell transplantation (HCT) with ex-vivo T cell receptor Alpha/Beta+ and CD19 depletion, intended to reduce GvHD risk.
Key results
The trial reported the following key measurements from the Alpha beta+ T cell depleted CD34+ stem cells group:
- The cumulative incidence of neutrophil engraftment and platelet engraftment was 66.7 Percentage of participants.
- The cumulative incidence of Grade III or Higher Acute GVHD was 0.0 Percentage of participants.
What this means
These early results from a small cohort of 3 participants suggest a promising safety profile for haploidentical hematopoietic cell transplantation using TCR Alpha/Beta and CD19 depletion, particularly with the observed 0.0 Percentage of participants for Grade III or Higher Acute GVHD. The neutrophil and platelet engraftment rate of 66.7 Percentage of participants indicates initial success in engraftment. While these findings are encouraging for reducing a major complication of HCT, the very limited sample size necessitates caution in interpretation. Further research with larger cohorts is essential to confirm these preliminary safety and efficacy signals and to fully assess the potential of this approach for patients with leukemia and related conditions.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05236764, titled "Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion", were posted on 2025-10-30 on clinicaltrials.gov.